QL1A Stock Chart & Stats
€12.32
-€0.39(-2.71%)
At close: 4:00 PM EDT
€12.32
-€0.39(-2.71%)
Day’s Range― - ―
52-Week Range€8.22 - €30.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€872.43M
Enterprise Value€3.89K
Total Cash (Recent Filing)€123.40M
Total Debt (Recent Filing)€3.08B
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 04, 2026EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.44
Shares Outstanding68,575,424
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.03
Price to Sales (P/S)0.73
P/FCF Ratio-23.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.95Price Target Upside5.09% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)0.66
Revenue Forecast (FY)€2.18B
Bulls Say, Bears Say
Bulls Say
Ex-China GrowthBroad growth across laboratories, immunohematology and point-of-care testing shows resilient demand outside China. Since roughly 90% of revenue comes from these markets, geographic diversification can reduce dependence on any single region.
EBITDA And Margin ExpansionStrong adjusted EBITDA growth and a substantial margin increase indicate operating leverage and effective cost control. If sustained, these improvements could strengthen profitability and provide greater capacity to fund innovation, debt reduction and commercial investment.
Lex/Neulixa CommercializationThe Lex acquisition adds a commercial growth opportunity in respiratory diagnostics. Progress on manufacturing, supply readiness and customer adoption supports a broader product platform, while increased placements and utilization could create recurring consumables revenue.
Bears Say
Persistent Losses And Cash BurnDeep losses and negative recent cash generation show that the business is not currently self-funding. Continued cash consumption can constrain research, commercial execution and debt reduction, making a durable return to profitability a critical execution requirement.
China Pricing UncertaintyPotential IVD pricing changes are causing customer destocking and slower purchases, with management expecting pressure to persist. Broader policy implementation could reduce pricing, volumes or margins in China and make regional revenue recovery difficult.
Leverage And Limited LiquidityElevated leverage combined with modest cash reserves reduces financial flexibility while profitability and cash conversion remain weak. Debt service and deleveraging priorities may limit investment capacity and increase sensitivity to operating setbacks.
QuidelOrtho News
QL1A FAQ
What was QuidelOrtho’s price range in the past 12 months?
QuidelOrtho lowest stock price was €8.22 and its highest was €30.40 in the past 12 months.
What is QuidelOrtho’s market cap?
QuidelOrtho’s market cap is €872.43M.
When is QuidelOrtho’s upcoming earnings report date?
QuidelOrtho’s upcoming earnings report date is Nov 04, 2026 which is in 66 days.
How were QuidelOrtho’s earnings last quarter?
QuidelOrtho released its earnings results on Aug 06, 2026. The company reported €0.111 earnings per share for the quarter, beating the consensus estimate of -€0.042 by €0.153.
Is QuidelOrtho overvalued?
According to Wall Street analysts QuidelOrtho’s price is currently Undervalued.
Does QuidelOrtho pay dividends?
QuidelOrtho does not currently pay dividends.
What is QuidelOrtho’s EPS estimate?
QuidelOrtho’s EPS estimate is 0.17.
How many shares outstanding does QuidelOrtho have?
QuidelOrtho has 68,575,424 shares outstanding.
What happened to QuidelOrtho’s price movement after its last earnings report?
QuidelOrtho reported an EPS of €0.111 in its last earnings report, beating expectations of -€0.042. Following the earnings report the stock price went down -28.357%.
Which hedge fund is a major shareholder of QuidelOrtho?
Currently, no hedge funds are holding shares in DE:QL1A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
QuidelOrtho Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
€12.95 (5.09% Upside)
€12.95 (5.09% Upside)
Blogger Sentiment
Neutral
DE:QL1A Sentiment 60%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
QuidelOrtho
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
QL1A Company Deck
QL1A Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed picture: solid underlying operational performance outside China (mid-single-digit growth ex-China, strong regional results, 21% YoY adjusted EBITDA growth, and margin expansion) and tangible progress on the Lex/Neulixa commercialization. Offsetting these positives were significant near-term headwinds — a 23% revenue decline in China driven by IVD pricing uncertainty, a softer respiratory season, negative operating and free cash flow in the quarter, withdrawal of free-cash-flow guidance, and elevated leverage (4.3x). Management emphasized disciplined cost actions, cash-conversion priorities, and mitigation plans, but the combination of China uncertainty and weak respiratory demand creates meaningful short-term risk even as core franchises remain resilient.View all DE:QL1A earnings summariesQL1A Stock 12 Month Forecast
Average Price Target
€12.95
▲(5.09% Upside)